>if things play out how Vertex was implying, Boceprevir may be a commercial flop.<
Well, VRTX is not exactly an unbiased observer :-)
Zebra’s Law does not really apply to Big Pharma, so I have to assume that SGP thinks Boceprevir has what it takes to compete. Telaprevir’s TID dosing and mediocre tolerability profile leave the door open, IMO.
Market Data 
Markets 
AI
